Navigation Links
TIGR® Matrix Surgical Mesh - Exhibited Ahead of Anticipated CE Mark Approval at European Hernia Society 2011, Ghent, Belgium

SINGAPORE, May 10, 2011 /PRNewswire/ -- Novus Scientific Pte. Ltd today announced that it will be exhibiting at EHS 2011 in Ghent, Belgium ahead of receiving its anticipated CE Mark approval this year for TIGR® Matrix Surgical Mesh, the World's 1st Long-Term Resorbable Synthetic Mesh.

To mark the occasion, a special presentation has been organized on Wednesday May 11th 2011 at the Zebrastraat venue in Ghent  (, featuring renowned surgeons; Dr. Frederik Berrevoet, Ghent University Hospital, who will lecture on "From polypropylene to TIGR® Matrix: towards the 'ideal' mesh" and Dr. Bruce Ramshaw, Halifax Health Medical Center, Daytona, FL, who will lecture on "Permanent mesh complications: How TIGR® Matrix can help". Henrik Magnusson, co-inventor of TIGR® Matrix will deliver a lecture on the design and properties of long-term resorbable synthetic mesh and answer questions from the audience on how this new class of 100% resorbable synthetic mesh is filling an important gap between biologics and permanent synthetics.

"EHS 2011 marks an important milestone for TIGR® Matrix and for Novus Scientific with presentation of the preliminary one year data from the First in Man clinical study. In this past year we have seen the growing acceptance by many surgeons of TIGR® Matrix as a new approach to soft tissue repair. With the anticipated approval of the CE Mark, we are excited to be able to offer TIGR® Matrix to leading surgeons and hospitals across Europe in the not too distant future," said Thomas Engstrom, CEO & President of Novus Scientific."We look forward to establishing a presence in Europe and to introducing TIGR® Matrix to the leading hernia centers once we attain the anticipated CE Mark. We have a major multicenter randomized controlled study planned with key opinion leaders and are very encouraged by the amount of attention TIGR® Matrix is receiving," said Tom Haeleydt, responsible for Sales & Marketing EMEA.TIGR® Matrix is the World's 1st Long-Term Resorbable Synthetic Mesh. US FDA cleared TIGR® Matrix Surgical Mesh for use in reinforcement of soft tissues where weakness exists in February 2010.

About Novus ScientificNovus Scientific ( is an innovator in the development and commercialization of resorbable synthetic medical devices. Global HQ is in Singapore while European Headquarters and the core R&D function are in Uppsala, Sweden.  The company's roots are Swedish as all the founders of Novus Scientific are previous owners / senior managers / members of the soft tissue-engineering project within Uppsala-based, Radi Medical Systems AB (now owned by St. Jude Medical Inc). The US Division, Novus Scientific, Inc. is headquartered near Boston, one of the world's foremost medical research cities. From this hub, Novus Scientific, Inc. will distribute TIGR® Matrix Surgical Mesh throughout the United States, Canada, and Latin America.

TIGR® is a trademark of Novus Scientific Pte. LtdCONTACT:

Mark Hawthorne: +44 7748 988705 - mark.hawthorne@novusscientific.comJames Archetto: +1-781-577-2599 -, both of Novus Scientific

SOURCE Novus Scientific Pte. Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Surgeons at University of California San Diego Perform 1st TRAM Flap Procedure in an International Multi-Center Study Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
2. National University Hospital Singapore Operates on Asias 1st TRAM Flap Patient Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
3. National University Hospital Singapore Receives DSRB Approval to Use TIGR® Matrix Surgical Mesh in a New Randomized Controlled TRAM Flap Study
4. Positive Findings From Excellagen Matrix Clinical Study Published in Peer-Reviewed Journal Wound Repair and Regeneration
5. Perrigo Enters Into Exclusive Sales and Distribution Agreement With AgaMatrix for Store Brand Blood Glucose Monitoring Products
6. Mylans Matrix Obtains License for Promising HIV/AIDS Treatment
7. Mylans Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets
8. Matrixx Initiatives, Inc. Announces End of Go-Shop Period
9. Matrixx Initiatives, Inc. Summarizes Ongoing Go-Shop Process and Board Reaffirms Recommendation
10. Matrixx Initiatives, Inc. Reports Fiscal 2011 Third Quarter Net Sales of $20.3 Million and Net Loss of $11.3 Million, or $(1.21) Per Share
11. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg
Post Your Comments:
(Date:11/26/2015)... 2015 Research and Markets ( ) has ... Market Outlook to 2019 - Rise in Cardiac Disorders and ... report to their offering. Boston ... scientific and others. --> The ... Boston scientific and others. ...
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Japanese Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... convenient way to dispense prescription medications at home, so he invented the patent-pending ... monitor and dispense prescription medications. In doing so, it could help to prevent ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... online platform for mental health and wellness consultation, has collaborated with a leading ... bridge the knowledge gap experienced by parents and bring advice from parenting experts ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
Breaking Medicine News(10 mins):